According to a ScienceDaily report, researchers studying osteoporosis have identified a receptor called GPR133 as a promising bone-building switch. An experimental compound, AP503, activated this receptor in mice and led to significantly stronger bones.
The apparent advantage of targeting GPR133 is that it appears to work in two ways at once: it boosts bone formation and limits bone loss. That dual effect is especially relevant for osteoporosis, where weakened bones are prone to fracture.
The same treatment has also been linked to stronger muscles, which the researchers described as an intriguing possibility—though the evidence so far comes from mice. Because this assessment is based on a single source, there are no conflicting findings to compare at this stage.